
## **Design hub for early phase drug discovery**

ÁKOS TARCSAY, IVÁN SOLT, ANDRÁS STRÁCZ



t Drug discovery is an iterative process of hypothesis construction relying on observations and validation through triggering new observations mainly by synthesis of new chemical entities. During the evolution of an idea to reach selection for synthesis, evidence and prediction results are collected and assessed and scrutinized by the project group. Therefore, the success of recent drug design depends on how data is turned into information and how much knowledge is extracted out of it. Accordingly, attempts toward connecting data sources or data, model building approaches may play crucial role in the preprocessing steps. Data analytics platforms with supervised or unsupervised methods are applied like linear fitting, clustering, pattern recognition or neural networks. These models are moving beyond the raw information and the extracted correlations can be exploited on novel, hypothetical structures to judge them

Synthesize

**Conclusion** The design hub fosters integration of knowledge and predictive models available in various forms into a design space to aid both the ideation and the decision making on synthesis targets. The first detailed example described in this presentation is the collection of analogues from vast amount of chemical space for freedom to operate analysis, supporting information collection based on similar structures or expansion by purchasing. Second, the preprocessed and transformed data relaying on assay results in the form of matched molecular pair analysis is shown to facilitate design towards reduced hERG liability analogues.

[1] Marvin Live, https://chemaxon.com/products/marvin-live [2] https://www.ebi.ac.uk/chembl/downloads [3] J. Hussain, C. Rea, J. Chem. Inf. Model., 2010, 50, 339–348 [4] A. Dalke, C. Kramer, J. Hert, J. Chem. Inf. Model., 2018, https://github.com/rdkit/mmpdb [5] JChem Web Services, https://chemaxon.com/products/jchem-engines [6] M. Hann, G. Keserű, Nat. Rev. Drug Discov., 2012, 11, 355–365 [7] T. Wager, X. Hou, P. Verhoest, A. Villalobos, ACS Chem Neurosci., 2010, 1, 435-449

atarcsay@chemaxon.com, isolt@chemaxon.com, astracz@chemaxon.com

